Trial Profile
Ablative STEreotactic RadiOtherapy wIth Durvalumab (MEDI4736). An Open Label Randomized Phase II Trial With Durvalumab Following Stereotactic Body Radiotherapy (SBRT) in Patients With Stage I Non-small Cell Lung Cancer (NSCLC)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 20 Nov 2023
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms ASTEROID
- 13 Nov 2023 Planned End Date changed from 1 Jul 2023 to 1 Jul 2024.
- 13 Nov 2023 Planned primary completion date changed from 1 Jul 2022 to 1 Jul 2024.
- 03 Mar 2021 Planned number of patients changed from 216 to 106.